Humacyte (HUMA) Stock Price, Quote, News & History | Benzinga

Humacyte Inc (HUMA) Stock Price, Quote, News & History

HUMANASDAQ

Trade with Public

Trade with Public

$0.7012

0.0395.89%

At close: Aug 25, 5:00 PM EST

$0.7069

0.005710.82%

After Hours: 7:59 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$0.66

Close

$0.70

Volume / Avg.

5.92M / 11.02M

Day Range

$0.66 - $0.73

52 Wk Range

0.53 - 2.55

Market Cap

$196.38M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

11.4%

Days to Cover

6.92

Recent Humacyte Inc News

Why Is Humacyte Stock Falling Thursday?

Humacyte (HUMA) stock plummets 22% despite positive Phase 3 ATEV trial data as investors react to a dilutive $50M share offering.

Vandana Singh

This Rockwell Automation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed outlook on top names. Needham downgrades CNTA, Baird downgrades PHR.

Avi Kapoor

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff.

Piero Cingari

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday

Avi Kapoor

Gold Falls 1%; ProKidney Shares Spike Higher

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-97.19M

Investing Cash Flow (TTM)

-367.00K

Financing Cash Flow (TTM)

89.43M

Free Cash Flow (TTM)

-97.56M

Capital Expenditure (TTM)

-367.00K

Net Change in Cash (TTM)

-8.13M

Analyst Trends and Forecast

3

May

4

Jun

1

Jul

0

0

0

0

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.6

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$171.40M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

61.09

PB Ratio (TTM)

5.92

Earnings Yield % (TTM)

-78.03%

Earnings Yield % (FWD)

-69.03%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.11

Company Debt

Total Debt

$36.32M

LT Debt

$36.32M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$1.51M

Total Cash

$79.90M

Debt to Equity

2.12

Issuance of Debt (TTM)

$38.27M

Repayment of Debt (TTM)

-$1.51M

Key Statistics

Open

$0.66

Close

$0.70

Volume / Avg.

5.92M / 11.02M

Day Range

$0.66 - $0.73

52 Wk Range

0.53 - 2.55

Market Cap

$196.38M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

52

Short Interest

11.4%

Days to Cover

6.92

About

Sector

Health Care

Industry

Biotechnology

Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactu...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Humacyte (HUMA) stock?

A

You can purchase shares of Humacyte (NASDAQ:HUMA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Humacyte (HUMA) competitors?

A

Other companies in Humacyte’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Humacyte (HUMA) stock?

A

Humacyte has a consensus price target of $8.81.

Q

What is the current price for Humacyte (HUMA)?

A

The stock price for Humacyte (NASDAQ: HUMA) is $0.706915 last updated August 25, 2026 at 7:59 PM EDT.

Q

Does Humacyte (HUMA) pay a dividend?

A

There are no upcoming dividends for Humacyte.

Q

When is Humacyte (NASDAQ:HUMA) reporting earnings?

A

Humacyte does not have any upcoming earnings scheduled.

Q

Is Humacyte (HUMA) going to split?

A

There is no upcoming split for Humacyte.

Q

What sector and industry does Humacyte (HUMA) operate in?

A

Humacyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.